ANKRD66

Across TCGA pan-cancer cohorts, ANKRD66 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated ANKRD66 data layer compared with 3 for mutation status.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher ANKRD66 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD66 expression acts as an unfavorable survival marker, although some lineages such as CHOL and LUAD show a favorable association.

CHOL, BLCA, and OV are the cancer types where ANKRD66 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	II,III,IV	1.000	0.127	.001	48	view →
BLCA	DFS	Tertile	IV	0.297	0.511	.001	45	view →
OV	DFS	Quartile	IV	0.345	0.666	.001	42	view →
LUAD	DFS	Tertile	All	0.838	0.731	.001	41	view →
SKCM	OS	Tertile	All	0.971	0.824	.007	30	view →
STAD	DFS	Tertile	All	0.537	0.752	.010	29	view →
PCPG	DFS	Tertile	All	0.305	0.857	.001	21	view →
UCEC	OS	Quartile	All	0.972	0.893	.002	20	view →
KIRC	DFS	Median	III,IV	0.818	0.689	.024	12	view →
READ	OS	Tertile	IV	0.077	1.000	.014	9	view →
ACC	DFS	Tertile	IV	0.633	0.129	.028	9	view →
THCA	OS	Quartile	All	0.970	0.989	.024	7	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

ANKRD66–CHOL (DFS)

Open the CHOL breakdown →